Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer

Journal of Clinical Oncology

Volumn 33, Issue 7, 2015, Pages 692-700

  Van Cutsem, Eric ^a   Lenz, Heinz Josef ^b   Köhne, Claus Henning ^c   Heinemann, Volker ^d   Tejpar, Sabine ^a   Melezínek, Ivan ^e   Beier, Frank ^e   Stroh, Christopher ^e   Rougier, Philippe ^f   Han Van Krieken, J ^g   Ciardiello, Fortunato ^h  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c KLINIKUM OLDENBURG   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e MERCK KGAA   (Germany)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^h SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; DNA; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; GUANOSINE TRIPHOSPHATASE; KRAS PROTEIN, HUMAN; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; NRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN; TUMOR MARKER;

ADULT; ALLELE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CODON; DEEP VEIN THROMBOSIS; DERMATITIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EMULSION; EXON; FATIGUE; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENETIC SCREENING; HUMAN; HUMAN TISSUE; INFUSION RELATED REACTION; LEUKOPENIA; MAGNETISM; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MICRODISSECTION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SKIN MANIFESTATION; TREATMENT OUTCOME; TREATMENT RESPONSE; AGED; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COLORECTAL NEOPLASMS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MUTATION; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROCEDURES; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; GENETIC TESTING; GTP PHOSPHOHYDROLASES; HUMANS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84925324704     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.59.4812     Document Type: Article

References (23)

1. Van Cutsem E, Köhne CH, Hitre E, et al: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408-1417, 2009
2. Van Cutsem E, Köhne CH, Láng I, et al: Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29:2011-2019, 2011
3. Bokemeyer C, Bondarenko I, Makhson A, et al: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663-671, 2009
4. Bokemeyer C, Bondarenko I, Hartmann JT, et al: Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: The OPUS study. Ann Oncol 22:1535-1546, 2011
5. Douillard JY, Siena S, Cassidy J, et al: Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J Clin Oncol 28:4697-4705, 2010
6. Forbes SA, Bindal N, Bamford S, et al: COSMIC: Mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 39: D945-D950, 2011
7. Douillard JY, Oliner KS, Siena S, et al: Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369:1023-1034, 2013
8. Chen CY, Shiesh SC, Wu SJ: Rapid detection of K-ras mutations in bile by peptide nucleic acidmediated PCR clamping and melting curve analysis: Comparison with restriction fragment length polymorphism analysis. Clin Chem 50:481-489, 2004
9. Dressman D, Yan H, Traverso G, et al: Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A 100: 8817-8822, 2003
10. Diehl F, Li M, Dressman D, et al: Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A 102:16368-16373, 2005
11. Diehl F, Schmidt K, Durkee KH, et al: Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients. Gastroenterology 135: 489-498, 2008
12. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
13. Bokemeyer C, Köhne CH, Ciardiello F, et al: Treatment outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab. J Clin Oncol 32, 2014 (suppl 15s; abstr 3505)
14. Peeters M, Price TJ, Cervantes A, et al: Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer. Ann Oncol 25:107-116, 2014
15. Peeters M, Oliner KS, Price TJ, et al: Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC). J Clin Oncol 32, 2014 (suppl; abstr LBA387)
16. National Comprehensive Cancer Network: NCCN Guidelines Colon Cancer (version 2.2015). http://www.nccn.org/professionals/physician-gls/f-guidelines.asp
17. Misale S, Yaeger R, Hobor S, et al: Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486:532-536, 2012
18. Schwartzberg LS, Rivera F, Karthaus M, et al: PEAK: A andomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 32: 2240-2247, 2014
19. Stintzing S, Jung A, Rossius L, et al: Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wildtype (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. Presented at the European Cancer Congress, Amsterdam, the Netherlands, September 27-October 1, 2013 (abstr LBA17)
20. Parsons BL, Myers MB: Personalized cancer treatment and the myth of KRAS wild-type colon tumors. Discov Med 15:259-267, 2013
21. Pekin D, Normand C, Kotsopoulos S, et al: Detection and quantification of minority subclones of KRAS on metastatic colorectal cancers by digital microfluidics: Therapeutic implications. Cancer Res 73, 2013 (abstr 4211)
22. Tougeron D, Lecomte T, Pagès JC, et al: Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer. Ann Oncol 24:1267-1273, 2013
23. Taly V, Laurent-Puig P, Pekin D, et al: Clinical significance of low frequency KRAS and BRAF subclones for advanced colon cancer management. Presented at the American Association for Cancer Research Annual Meeting, San Diego, CA, April 5-9, 2014